scholarly journals Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies

2018 ◽  
Vol 35 (4) ◽  
pp. 563-576 ◽  
Author(s):  
Edouard J. Louis ◽  
Walter Reinisch ◽  
David A. Schwartz ◽  
Robert Löfberg ◽  
Anne M. Robinson ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Studies ◽  
Pooled Analysis ◽  
Extraintestinal Manifestations

Mo1791 Adalimumab Treatment Reduces Extraintestinal Manifestations in Patients With Moderate to Severe Crohn's Disease: A Pooled Analysis

2016 ◽  
Vol 150 (4) ◽  
pp. S777 ◽  
Author(s):  
Edouard Louis ◽  
Robert Lofberg ◽  
Walter Reinisch ◽  
David A. Schwartz ◽  
Jen-Fue Maa ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Pooled Analysis ◽  
Extraintestinal Manifestations ◽  
Adalimumab Treatment

scholarly journals DOP019 Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s disease: a GEMINI 2 post hoc analysis

2017 ◽  
Vol 11 (suppl_1) ◽  
pp. S36-S38
Author(s):  
B.G. Feagan ◽  
W.J. Sandborn ◽  
J.-F. Colombel ◽  
S. O’Byrne ◽  
J.M. Khalid ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Extraintestinal Manifestations ◽  
Post Hoc Analysis ◽  
Post Hoc

Extraintestinal Manifestations of Crohn’s Disease

Digestion ◽  
2007 ◽  
Vol 76 (2) ◽  
pp. 141-148 ◽  
Author(s):  
Pascal Juillerat ◽  
Christian Mottet ◽  
Valérie Pittet ◽  
Florian Froehlich ◽  
Christian Felley ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Extraintestinal Manifestations

scholarly journals Extraintestinal manifestations of Crohn’s disease

2016 ◽  
Vol 3 ◽  
pp. 218-221
Author(s):  
Bartosz Wójcik ◽  
Karolina Loga ◽  
Marcin Włodarczyk ◽  
Aleksandra Sobolewska-Włodarczyk ◽  
Milena Padysz ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Extraintestinal Manifestations

scholarly journals Keep an Eye Out for Crohn’s Disease: Orbital Myositis as the Initial Sign before Gastrointestinal Manifestations

2020 ◽  
Author(s):  
Gilles Jadd Hoilat ◽  
Abinash Subedi ◽  
Mohamad Fekredeen Ayas ◽  
Nuri Ozden
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Pseudotumor Cerebri ◽  
Extraintestinal Manifestations ◽  
Gastrointestinal Manifestations ◽  
Orbital Myositis ◽  
Ocular Manifestations ◽  
Initial Sign ◽  
Intestinal Symptoms ◽  
Work Up

Extraintestinal manifestations of Crohn's disease sometimes occur and can present prior to intestinal symptoms. Ocular manifestations of Crohn's disease are considered rare, with orbital myositis an even rarer manifestation with only a handful of cases reported in the literature. We present the case of a young woman who was diagnosed with orbital myositis, which was initially attributed to pseudotumor cerebri after an extensive negative work-up. Months later, the patient presented with haematochezia, and was subsequently diagnosed with Crohn's disease.

scholarly journals Inability to walk: a rare presentation of Crohn’s disease

2020 ◽  
Vol 7 (1) ◽  
pp. e000526
Author(s):  
Elmer Hoekstra ◽  
Rudolf Keunen ◽  
Michael van der Voorn
Keyword(s):  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Unusual Case ◽  
Extraintestinal Manifestations ◽  
Neurological Manifestations ◽  
Rare Presentation ◽  
Inflammatory Bowel

A wide variety of extraintestinal manifestations of inflammatory bowel disease (IBD) have been described, with joint or dermatological complaints as most prevalent. However, also neurological manifestations can occur, which are rarely recognised and therefore under-reported. We present an very unusual case of a young man who presented with the inability to walk, as a first presentations of IBD.

scholarly journals Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study

2020 ◽  
Vol 7 (1) ◽  
pp. e000351 ◽  
Author(s):  
Ignacio Marin-Jimenez ◽  
Guillermo Bastida ◽  
Ana Forés ◽  
Esther Garcia-Planella ◽  
Federico Argüelles-Arias ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Chronic Obstructive ◽  
Extraintestinal Manifestations ◽  
Multivariate Logistic Regression ◽  
Obstructive Pulmonary Disease ◽  
Inflammatory Bowel

ObjectiveTo evaluate the impact of comorbidities and extraintestinal manifestations of inflammatory bowel disease on the response of patients with inflammatory bowel disease to antitumour necrosis factor alpha (anti-TNFα) therapy.DesignData from 310 patients (194 with Crohn’s disease and 116 with ulcerative colitis) treated consecutively with the first anti-TNFα in 24 Spanish hospitals were retrospectively analysed. Univariate and multivariate logistic regression analyses were performed to assess the associations between inflammatory bowel disease comorbidities and extraintestinal manifestations with anti-TNFα treatment outcomes. Key clinical features, such as type of inflammatory bowel disease and concomitant treatments, were included as fixed factors in the model.ResultsMultivariate logistic regression analyses (OR, 95% CI) showed that chronic obstructive pulmonary disease (2.67, 1.33 to 5.35) and hepato-pancreato-biliary diseases (1.87, 1.48 to 2.36) were significantly associated with primary non-response to anti-TNFα, as was the use of corticosteroids and the type of inflammatory bowel disease (ulcerative colitis vs Crohn’s disease). It was also found that myocardial infarction (3.30, 1.48 to 7.35) and skin disease (2.73, 1.42 to 5.25) were significantly associated with loss of response, along with the use of corticosteroids and the type of inflammatory bowel disease (ulcerative colitis vs Crohn’s disease).ConclusionsOur results suggest that the presence of some comorbidities in patients with inflammatory bowel disease, such as chronic obstructive pulmonary disease and myocardial infarction, and of certain extraintestinal manifestations of inflammatory bowel disease, such as hepato-pancreato-biliary conditions and skin diseases, appear to be related to failure to anti-TNFα treatment. Therefore, their presence should be considered when choosing a treatment.Trial registration numberNCT02861118.

Sign in / Sign up

Export Citation Format

Share Document